Background: Health-related quality of life (HRQoL) and productivity of patients with confirmed severe asthma (SA) have not been well characterized in large, real-world populations.
Purpose: To characterize SA impact on HRQoL, work productivity, and activity impairment in a large, real-world cohort in the United States (US).
Methods: CHRONICLE is an observational study of specialist-treated adults (≥ 18 years) in the US with SA receiving biologics or maintenance systemic corticosteroids (mSCS), or those persistently uncontrolled by high-dosage inhaled corticosteroids with additional controllers (HD ICS+). At enrollment, patients completed the St. George’s Respiratory Questionnaire (SGRQ) and Work Productivity and Activity Impairment (WPAI) questionnaire. Results were analyzed for those enrolled between February 2018 and February 2020.
Results: Among patients who completed enrollment questionnaires (n = 1109), mean age was 54 years and most were women (70%). Among SGRQ respondents (n = 960), mean (SD) total score was 43 (23); 51% reported good/very good health. Among WPAI respondents (n = 1057; 566 employed), mean (SD) overall work impairment was 21% (25). Patients receiving biologics (vs mSCS, HD ICS+ only) had better SGRQ total scores (38 vs 59, 48) and lower work impairment (17% vs 34%, 27%). Patients with better SGRQ activity scores relative to symptom scores had better SGRQ impacts scores, total scores, and reported better overall health.
Conclusion: SA significantly affects HRQoL, work productivity, and activity. The SGRQ is a valuable research instrument for evaluating HRQoL in SA. Due to its association with HRQoL and overall health, activity impairment should be a focus when monitoring patients’ disease control.
Study Registration: ClinicalTrials.gov Identifier: NCT03373045.



中文翻译：

---

美国严重哮喘患者的健康相关生活质量和生产力

背景：在现实世界的大量人群中，尚未对确诊为严重哮喘 (SA) 患者的健康相关生活质量 (HRQoL) 和生产力进行很好的表征。
目的：在美国（US）的一个大型真实世界队列中描述 SA 对 HRQoL、工作效率和活动障碍的影响。
方法：CHRONICLE 是一项针对美国接受专科治疗的成人（≥ 18 岁）的观察性研究，其中 SA 接受生物制剂或维持性全身性皮质类固醇 (mSCS)，或那些持续不受高剂量吸入皮质类固醇和额外控制器 (HD ICS+) 控制的人。入组时，患者完成了圣乔治呼吸问卷 (SGRQ) 和工作效率和活动障碍 (WPAI) 问卷。对 2018 年 2 月至 2020 年 2 月期间入组的人的结果进行了分析。
结果：在完成登记问卷的患者（n = 1109）中，平均年龄为 54 岁，大多数为女性（70%）。在 SGRQ 受访者 (n = 960) 中，平均 (SD) 总分为 43 (23)；51% 的人表示健康状况良好/非常好。在 WPAI 受访者（n = 1057；566 人受雇）中，平均 (SD) 总体工作障碍为 21% (25)。接受生物制剂的患者（与 mSCS 相比，仅 HD ICS+）具有更好的 SGRQ 总分（38 对 59、48）和更低的工作障碍（17% 对 34%、27%）。与症状评分相比，SGRQ 活动评分更好的患者具有更好的 SGRQ 影响评分、总分，并报告了更好的整体健康状况。
结论：SA 显着影响 HRQoL、工作效率和活动。SGRQ 是评估 SA 中 HRQoL 的有价值的研究工具。由于其与 HRQoL 和整体健康有关，因此在监测患者疾病控制时，活动障碍应成为重点。
研究注册： ClinicalTrials.gov 标识符：NCT03373045。